Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
Mark Lebwohl, Arthur Kavanaugh, April W. Armstrong, et al.
American Journal of Clinical Dermatology (2015) Vol. 17, Iss. 1, pp. 87-97
Open Access | Times Cited: 197

Showing 1-25 of 197 citing articles:

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Kristian Reich, April W. Armstrong, Peter Foley, et al.
Journal of the American Academy of Dermatology (2017) Vol. 76, Iss. 3, pp. 418-431
Open Access | Times Cited: 626
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Anniina Virtanen, T. Haikarainen, Juuli Raivola, et al.
BioDrugs (2019) Vol. 33, Iss. 1, pp. 15-32
Open Access | Times Cited: 245
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis
April W. Armstrong, Michael Siegel, Jerry Bagel, et al.
Journal of the American Academy of Dermatology (2016) Vol. 76, Iss. 2, pp. 290-298
Open Access | Times Cited: 163
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Richard B. Warren, Ulrich Mrowietz, Ralph von Kiedrowski, et al.
The Lancet (2016) Vol. 389, Iss. 10068, pp. 528-537
Open Access | Times Cited: 122
Interleukin‐17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities
James G. Krueger, Patrick M. Brunner
Experimental Dermatology (2017) Vol. 27, Iss. 2, pp. 115-123
Open Access | Times Cited: 99
Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima, et al.
The Journal of Dermatology (2018) Vol. 45, Iss. 9, pp. 1053-1062
Open Access | Times Cited: 98
Clinical Goals and Barriers to Effective Psoriasis Care
Bruce Strober, Joelle M. van der Walt, April W. Armstrong, et al.
Dermatology and Therapy (2018) Vol. 9, Iss. 1, pp. 5-18
Open Access | Times Cited: 84
Itch: an under‐recognized problem in psoriasis
Boni E. Elewski, Andrew Alexis, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology (2019) Vol. 33, Iss. 8, pp. 1465-1476
Closed Access | Times Cited: 78
Molecular and Cellular Mechanisms of Itch in Psoriasis
Eriko Komiya, Mitsutoshi Tominaga, Yayoi Kamata, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8406-8406
Open Access | Times Cited: 76
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Mark S. Talamonti, Andrea Chiricozzi, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 1, pp. 235-252
Open Access | Times Cited: 57
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)
Mette Gyldenløve, Howraman Meteran, Jennifer Astrup Sørensen, et al.
The Lancet Regional Health - Europe (2023) Vol. 30, pp. 100639-100639
Open Access | Times Cited: 26
Psoriasis and Atopic Dermatitis
C.E.M. Griffiths, Peter van de Kerkhof, Magdalena Czarnecka‐Operacz
Dermatology and Therapy (2017) Vol. 7, Iss. S1, pp. 31-41
Open Access | Times Cited: 74
Psoriatic arthritis for dermatologists
Alice B. Gottlieb, Joseph F. Merola
Journal of Dermatological Treatment (2019) Vol. 31, Iss. 7, pp. 662-679
Open Access | Times Cited: 72
Psoriasis and Co-morbidity
Mina Amin, Erica B. Lee, Tsen‐Fang Tsai, et al.
Acta Dermato Venereologica (2020) Vol. 100, Iss. 3, pp. 81-87
Open Access | Times Cited: 69
Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis
Jean Christopher Chamcheu, Imtiaz A. Siddiqui, Vaqar M. Adhami, et al.
International Journal of Nanomedicine (2018) Vol. Volume 13, pp. 4189-4206
Open Access | Times Cited: 65
Dihydroartemisinin ameliorates psoriatic skin inflammation and its relapse by diminishing CD8+ T-cell memory in wild-type and humanized mice
Yuchao Chen, Yuhong Yan, Huazhen Liu, et al.
Theranostics (2020) Vol. 10, Iss. 23, pp. 10466-10482
Open Access | Times Cited: 65
Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey
April W. Armstrong, Barbra Bohannan, S. Mburu, et al.
Dermatology (2023) Vol. 239, Iss. 4, pp. 621-634
Open Access | Times Cited: 20
SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis
Rahul Pandey, Marina Bakay, Hákon Hákonarson
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
J.M. Carrascosa, Ira Jacobs, Danielle Petersel, et al.
Dermatology and Therapy (2018) Vol. 8, Iss. 2, pp. 173-194
Open Access | Times Cited: 56
Psoriasis: Overview and Diagnosis
Grace W. Kimmel, Mark Lebwohl
Updates in clinical dermatology (2018), pp. 1-16
Closed Access | Times Cited: 54
Biologics and Psoriasis
Hee J. Kim, Mark Lebwohl
Dermatologic Clinics (2018) Vol. 37, Iss. 1, pp. 29-36
Closed Access | Times Cited: 52
Toll-like receptor 7/8 agonists stimulate plasmacytoid dendritic cells to initiate TH17-deviated acute contact dermatitis in human subjects
Natalie Garzorz‐Stark, Felix Lauffer, Linda Krause, et al.
Journal of Allergy and Clinical Immunology (2017) Vol. 141, Iss. 4, pp. 1320-1333.e11
Open Access | Times Cited: 51
Patient perceptions of clear/almost clear skin in moderate‐to‐severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey
April W. Armstrong, Suzanne Jarvis, Wolf‐­Henning Boehncke, et al.
Journal of the European Academy of Dermatology and Venereology (2018) Vol. 32, Iss. 12, pp. 2200-2207
Open Access | Times Cited: 51
Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists
Jerry Bagel, Sergio Schwartzman
American Journal of Clinical Dermatology (2018) Vol. 19, Iss. 6, pp. 839-852
Open Access | Times Cited: 51
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
Matteo Megna, Sonia Sofìa Ocampo‐Garza, Luca Potestio, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1482-1482
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top